Bristol-Myers Squibb Company
Immunotherapeutic dosing regimens comprising pomalidomide and an anti-CS1 antibody for treating cancer

Abstract:

The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with one or more immunotherapeutic agents.